Market Overview:
The global long acting insulins market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes, rising awareness about diabetes and its treatment, and technological advancements in insulin delivery devices. Based on type, the global long acting insulins market is segmented into insulin glargine, insulin detemir, insulin degludec, and long-acting animal insulins. Insulin glargine is expected to account for the largest share of the global long acting insulins market in 2018. This segment is also projected to grow at a CAGR of 6.8% during the forecast period from 2018 to 2030 due to its high efficacy and longer duration of action as compared with other types of insulin analogs available in the market. Based on application, the global long acting insulins market is segmented into home use, medical institutions (hospitals & clinics), and others (research institutes & pharmaceutical companies).
Product Definition:
Long Acting Insulins are types of insulin that work over a long period of time to help control blood sugar levels. They are important because they can help to prevent spikes in blood sugar levels after meals.
Insulin Glargine:
Insulin glargine is a long-acting insulin, which was approved by the U.S. FDA in 2003 as an injection for diabetic patients who require more than 20 units of insulin per day and have difficulty in maintaining an adequate blood glucose level through oral dosage form.
The drug has been found to be effective when used with other anti-diabetic drugs or alone as a single daily injection.
Insulin Determir:
Insulin determir is an anti-diabetic drug that works by blocking the activity of insulin in the body. It does not affect the ability of sugar to enter the blood cells, but it prevents its conversion into fat. Insulin is a hormone which facilitates entry of sugar into blood cells and also helps in storing energy from food as fat.
Application Insights:
The medical institutions segment held the largest share of the global market in 2017. This is due to a high prevalence of diabetes and increasing awareness about its treatment. Long acting insulin is used by diabetic patients who have difficulty in taking injections frequently or cannot do so at all due to work or other commitments. These patients are supposed to take two doses a day, one before breakfast and another one before dinner, which makes it difficult for them to use short-acting insulin as they have already taken their dose for the day. In such cases, LAIIs help by providing an alternative source of insulin that can be used multiple times without any prior notice as it remains active until 12 hours after injection time.
Medical application dominated with over 30% share owing to growing usage of long acting insulins for treating type 1.
Regional Analysis:
Europe dominated the global market in 2017 owing to factors such as technological advancements, presence of major insulin delivery device manufacturers and high prevalence of diabetes. In addition, increasing number of product launches is also expected to drive the regional market over the forecast period. Asia Pacific is expected to witness lucrative growth during the forecast period due to rising disposable income levels and improving healthcare infrastructure in emerging countries such as China & India. Moreover, growing awareness about advanced therapies for diabetes management will propel regional growth further. The U.S.
Asia Pacific was estimated at USD X million in 2017.
Growth Factors:
- Increasing incidence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is primarily due to the changing lifestyle and dietary habits of people across the world. As a result, there is an increased demand for long-acting insulin products that can help in better glycemic control.
- Technological advancements: The pharmaceutical industry is constantly making progress in terms of technology, which has led to the development of novel long-acting insulin products with improved pharmacokinetic and pharmacodynamic profiles. This has helped to boost the growth prospects of the Long Acting Insulins market.
- Rising awareness about diabetes: There is a growing awareness among people about diabetes and its associated risks. This has led to an increase in demand for effective treatment options, including long-acting insulin products.
Scope Of The Report
Report Attributes
Report Details
Report Title
Long Acting Insulins Market Research Report
By Type
Insulin Glargine, Insulin Determir, Insulin Degludec, Long Acting Animal Insulin
By Application
Home Use, Medical Institutions, Others
By Companies
Novo Nordisk, Sanofi, Wockhardt UK
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
217
Number of Tables & Figures
152
Customization Available
Yes, the report can be customized as per your need.
Global Long Acting Insulins Market Report Segments:
The global Long Acting Insulins market is segmented on the basis of:
Types
Insulin Glargine, Insulin Determir, Insulin Degludec, Long Acting Animal Insulin
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Home Use, Medical Institutions, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novo Nordisk
- Sanofi
- Wockhardt UK
Highlights of The Long Acting Insulins Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Insulin Glargine
- Insulin Determir
- Insulin Degludec
- Long Acting Animal Insulin
- By Application:
- Home Use
- Medical Institutions
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Long Acting Insulins Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Long acting insulins are a type of insulin that lasts for several hours after being injected. They are used to control blood sugar levels in people with diabetes.
Some of the key players operating in the long acting insulins market are Novo Nordisk, Sanofi, Wockhardt UK.
The long acting insulins market is expected to grow at a compound annual growth rate of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Long Acting Insulins Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Long Acting Insulins Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Long Acting Insulins Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Long Acting Insulins Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Long Acting Insulins Market Size & Forecast, 2018-2028
4.5.1 Long Acting Insulins Market Size and Y-o-Y Growth
4.5.2 Long Acting Insulins Market Absolute $ Opportunity
Chapter 5 Global Long Acting Insulins Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Long Acting Insulins Market Size Forecast by Type
5.2.1 Insulin Glargine
5.2.2 Insulin Determir
5.2.3 Insulin Degludec
5.2.4 Long Acting Animal Insulin
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Long Acting Insulins Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Long Acting Insulins Market Size Forecast by Applications
6.2.1 Home Use
6.2.2 Medical Institutions
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Long Acting Insulins Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Long Acting Insulins Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Long Acting Insulins Analysis and Forecast
9.1 Introduction
9.2 North America Long Acting Insulins Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Long Acting Insulins Market Size Forecast by Type
9.6.1 Insulin Glargine
9.6.2 Insulin Determir
9.6.3 Insulin Degludec
9.6.4 Long Acting Animal Insulin
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Long Acting Insulins Market Size Forecast by Applications
9.10.1 Home Use
9.10.2 Medical Institutions
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Long Acting Insulins Analysis and Forecast
10.1 Introduction
10.2 Europe Long Acting Insulins Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Long Acting Insulins Market Size Forecast by Type
10.6.1 Insulin Glargine
10.6.2 Insulin Determir
10.6.3 Insulin Degludec
10.6.4 Long Acting Animal Insulin
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Long Acting Insulins Market Size Forecast by Applications
10.10.1 Home Use
10.10.2 Medical Institutions
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Long Acting Insulins Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Long Acting Insulins Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Long Acting Insulins Market Size Forecast by Type
11.6.1 Insulin Glargine
11.6.2 Insulin Determir
11.6.3 Insulin Degludec
11.6.4 Long Acting Animal Insulin
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Long Acting Insulins Market Size Forecast by Applications
11.10.1 Home Use
11.10.2 Medical Institutions
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Long Acting Insulins Analysis and Forecast
12.1 Introduction
12.2 Latin America Long Acting Insulins Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Long Acting Insulins Market Size Forecast by Type
12.6.1 Insulin Glargine
12.6.2 Insulin Determir
12.6.3 Insulin Degludec
12.6.4 Long Acting Animal Insulin
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Long Acting Insulins Market Size Forecast by Applications
12.10.1 Home Use
12.10.2 Medical Institutions
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Long Acting Insulins Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Long Acting Insulins Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Long Acting Insulins Market Size Forecast by Type
13.6.1 Insulin Glargine
13.6.2 Insulin Determir
13.6.3 Insulin Degludec
13.6.4 Long Acting Animal Insulin
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Long Acting Insulins Market Size Forecast by Applications
13.10.1 Home Use
13.10.2 Medical Institutions
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Long Acting Insulins Market: Competitive Dashboard
14.2 Global Long Acting Insulins Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novo Nordisk
14.3.2 Sanofi
14.3.3 Wockhardt UK
